Merck KGaA, Darmstadt, Germany regains exclusive worldwide rights to develop, manufacture and commercialize BAVENCIO from Pfizer Deal is the latest exam...
Patients treated suffered from platinum resistant/refractory ovarian cancer Previous PD-(L)1/CTLA-4 combinations have reported only 3-10% re...
ncyte (Nasdaq:INCY) announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved Pemazyre® (pemigatinib), a selective fi...
HANSIZHUANG (serplulimab) is the first anti-PD-1 mAb for the first-line treatment of small cell lung cancer (SCLC) The EC and the FDA previously granted...
CancerVAX, Inc., developer of a breakthrough universal cancer vaccine that will use the body’s immune system to fight cancer, today announced that it...
The U.S. Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) for Jardiance® (empagliflozin) tablets, which ...
As part of the transaction, certain operational obligations of the parties related to GS-1811, an anti-CCR8 antibody, set forth in the license agreement ha...
While humans and mice generate antibodies that require heavy and light chain pairing to be functional, camels and sharks generate heavy-chain-only antibodi...
© 2025 Biopharma Boardroom. All Rights Reserved.
